{"id":2324,"date":"2017-07-03T07:43:47","date_gmt":"2017-07-03T07:43:47","guid":{"rendered":"https:\/\/lynxee.consulting\/?p=2324\/"},"modified":"2017-07-12T07:44:55","modified_gmt":"2017-07-12T07:44:55","slug":"europe-new-efsa-gd-on-dermal-absorption","status":"publish","type":"post","link":"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/","title":{"rendered":"EUROPE: New EFSA GD on Dermal absorption"},"content":{"rendered":"

EFSA was asked by the European Commission to assess the scienti\ufb01c quality of newly available human <\/span>in vitro<\/span><\/i> studies on dermal absorption and, based on the evaluation of the studies, to revise the EFSA PPR Panel guidance on dermal absorption (<\/span>EFSA PPR Panel, 2012<\/span><\/a>).<\/span><\/p>\n

The guidance proposed new default values to be used in absence of experimental data. Since the new available data clearly show that dermal absorption is significantly affected by the concentration of active substance in the product and by the type of formulation, the<\/span> new default values<\/b> are categorised by formulation type or concentrated and diluted pesticide formulations. <\/span><\/p>\n

A comparison of new and current default values is presented below:<\/span><\/p>\n

2017 Guidance Document:<\/strong><\/p>\n\n\n\n\n\n\n\n
Formulation type<\/b><\/td>\nConcentration status<\/b><\/td>\nDefault dermal absorption \u00a0value<\/b><\/td>\n<\/tr>\n
Organic solvent-based(a) or other(b)<\/span><\/td>\nConcentrate<\/span><\/td>\n25%<\/b><\/td>\n<\/tr>\n
Dilution<\/span><\/td>\n70%<\/b><\/td>\n<\/tr>\n
Water-based(c) or solid(d)<\/span><\/td>\nConcentrate<\/span><\/td>\n10%<\/b><\/td>\n<\/tr>\n
Dilution<\/span><\/td>\n50%<\/b><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

(a): Formulation types: emulsi\ufb01able concentrate (EC), emulsion, oil in water (EW), suspo-emulsion (SE), dispersible concentrate (DC), oil miscible liquids (OL\/OF), oil-based suspension concentrates (OD), emulsion for seed treatment (ES), microemulsion (ME).<\/span><\/p>\n

(b): Formulation types: bait concentrate (CB), capsule suspension (CS), gel for direct application (GEL\/GD), bait, ready for use (RB), mixture of capsule suspension and suspension concentrate (ZC), seed coated with a pesticide (PS), experimental solution of active substances in solvent (AI).<\/span><\/p>\n

(c): Formulation types: soluble concentrate (SL), suspension concentrate (SC), \ufb02owable concentrate for seed treatment (FS), \ufb02owable (FL) (=SC).<\/span><\/p>\n

(d): Formulation types: wettable powder (WP), water-dispersible granules (WG\/WDG), water-soluble granules (SG), water-soluble powder (SP), powder for dry seed treatment (DS).<\/span><\/p>\n

 <\/p>\n

2012 Guidance Document:<\/strong><\/p>\n\n\n\n\n\n\n
<\/td>\nDefault dermal absorption value<\/b><\/td>\n<\/tr>\n
Concentrate<\/span><\/p>\n

(> 5% a.s., 50 g\/kg for solids or 50 g\/L for liquids)<\/span><\/td>\n

25%<\/b><\/td>\n<\/tr>\n
Dilution<\/span><\/p>\n

(\u2264 5% a.s.)<\/span><\/td>\n

75%<\/b><\/td>\n<\/tr>\n
Active substance with<\/span><\/p>\n

log Pow < -1 or > 4 and MW > 500<\/span><\/td>\n

10%<\/b><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

A <\/span>technical meeting with stakeholders<\/span><\/a> will be held in Parma on 27-28 September 2017 to explain how the document differs from the guidance issued in 2012, answer questions and collect feedback.<\/span><\/p>\n

 <\/p>\n

To download: <\/b><\/p>\n

Guidance on dermal absorption<\/span><\/a> (EFSA Guidance, 24\/05\/2017)<\/span><\/p>\n

Outcome of the public consultation on the draft EFSA Guidance on dermal absorption<\/span><\/a> (EFSA Technical report, 24\/05\/2017)<\/span><\/p>\n

 <\/p>\n

Lynxee consulting<\/b>\u2019s team is at your disposal to answer your questions.<\/span><\/p>\n

Contact us!<\/b> https:\/\/lynxee.consulting\/en\/contact\/<\/span><\/a><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

EFSA was asked by the European Commission to assess the scienti\ufb01c quality of newly available human in vitro studies on dermal absorption and, based on the [\u2026]<\/span><\/p>\n","protected":false},"author":4,"featured_media":2321,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36],"tags":[195],"class_list":["post-2324","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-regulation","tag-human-health"],"yoast_head":"\nEUROPE: New EFSA GD on Dermal absorption - Lynxee consulting<\/title>\n<meta name=\"description\" content=\"EFSA was asked by the European Commission to assess the scienti\ufb01c quality of newly available human in vitro studies on dermal absorption and, based on the\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EUROPE: New EFSA GD on Dermal absorption - Lynxee consulting\" \/>\n<meta property=\"og:description\" content=\"EFSA was asked by the European Commission to assess the scienti\ufb01c quality of newly available human in vitro studies on dermal absorption and, based on the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/\" \/>\n<meta property=\"og:site_name\" content=\"Lynxee consulting\" \/>\n<meta property=\"article:published_time\" content=\"2017-07-03T07:43:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-07-12T07:44:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/07\/mosquito-bite-2117420_1920.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Vianay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Vianay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-efsa-gd-on-dermal-absorption\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-efsa-gd-on-dermal-absorption\\\/\"},\"author\":{\"name\":\"\u00c9milie Vianay\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/4e2e7b2258dcb671ad7fbafa59128a5d\"},\"headline\":\"EUROPE: New EFSA GD on Dermal absorption\",\"datePublished\":\"2017-07-03T07:43:47+00:00\",\"dateModified\":\"2017-07-12T07:44:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-efsa-gd-on-dermal-absorption\\\/\"},\"wordCount\":370,\"image\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-efsa-gd-on-dermal-absorption\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2017\\\/07\\\/mosquito-bite-2117420_1920.jpg\",\"keywords\":[\"Human Health\"],\"articleSection\":[\"Regulation\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-efsa-gd-on-dermal-absorption\\\/\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-efsa-gd-on-dermal-absorption\\\/\",\"name\":\"EUROPE: New EFSA GD on Dermal absorption - Lynxee consulting\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-efsa-gd-on-dermal-absorption\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-efsa-gd-on-dermal-absorption\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2017\\\/07\\\/mosquito-bite-2117420_1920.jpg\",\"datePublished\":\"2017-07-03T07:43:47+00:00\",\"dateModified\":\"2017-07-12T07:44:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/4e2e7b2258dcb671ad7fbafa59128a5d\"},\"description\":\"EFSA was asked by the European Commission to assess the scienti\ufb01c quality of newly available human in vitro studies on dermal absorption and, based on the\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-efsa-gd-on-dermal-absorption\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-efsa-gd-on-dermal-absorption\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-efsa-gd-on-dermal-absorption\\\/#primaryimage\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2017\\\/07\\\/mosquito-bite-2117420_1920.jpg\",\"contentUrl\":\"https:\\\/\\\/lynxee.consulting\\\/wp-content\\\/uploads\\\/2017\\\/07\\\/mosquito-bite-2117420_1920.jpg\",\"width\":1920,\"height\":1440},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/europe-new-efsa-gd-on-dermal-absorption\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EUROPE: New EFSA GD on Dermal absorption\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#website\",\"url\":\"https:\\\/\\\/lynxee.consulting\\\/\",\"name\":\"Lynxee consulting\",\"description\":\"Innovative support for regulatory issues\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lynxee.consulting\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/lynxee.consulting\\\/#\\\/schema\\\/person\\\/4e2e7b2258dcb671ad7fbafa59128a5d\",\"name\":\"\u00c9milie Vianay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1596a005fffeecedac691970c998238f8639d0641c3e3c40fcc9044ca512b7f3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1596a005fffeecedac691970c998238f8639d0641c3e3c40fcc9044ca512b7f3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1596a005fffeecedac691970c998238f8639d0641c3e3c40fcc9044ca512b7f3?s=96&d=mm&r=g\",\"caption\":\"\u00c9milie Vianay\"},\"sameAs\":[\"https:\\\/\\\/lynxee.consulting\"],\"url\":\"https:\\\/\\\/lynxee.consulting\\\/en\\\/author\\\/emilie\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EUROPE: New EFSA GD on Dermal absorption - Lynxee consulting","description":"EFSA was asked by the European Commission to assess the scienti\ufb01c quality of newly available human in vitro studies on dermal absorption and, based on the","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/","og_locale":"en_US","og_type":"article","og_title":"EUROPE: New EFSA GD on Dermal absorption - Lynxee consulting","og_description":"EFSA was asked by the European Commission to assess the scienti\ufb01c quality of newly available human in vitro studies on dermal absorption and, based on the","og_url":"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/","og_site_name":"Lynxee consulting","article_published_time":"2017-07-03T07:43:47+00:00","article_modified_time":"2017-07-12T07:44:55+00:00","og_image":[{"width":1920,"height":1440,"url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/07\/mosquito-bite-2117420_1920.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Vianay","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Vianay","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/#article","isPartOf":{"@id":"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/"},"author":{"name":"\u00c9milie Vianay","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/4e2e7b2258dcb671ad7fbafa59128a5d"},"headline":"EUROPE: New EFSA GD on Dermal absorption","datePublished":"2017-07-03T07:43:47+00:00","dateModified":"2017-07-12T07:44:55+00:00","mainEntityOfPage":{"@id":"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/"},"wordCount":370,"image":{"@id":"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/#primaryimage"},"thumbnailUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/07\/mosquito-bite-2117420_1920.jpg","keywords":["Human Health"],"articleSection":["Regulation"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/","url":"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/","name":"EUROPE: New EFSA GD on Dermal absorption - Lynxee consulting","isPartOf":{"@id":"https:\/\/lynxee.consulting\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/#primaryimage"},"image":{"@id":"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/#primaryimage"},"thumbnailUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/07\/mosquito-bite-2117420_1920.jpg","datePublished":"2017-07-03T07:43:47+00:00","dateModified":"2017-07-12T07:44:55+00:00","author":{"@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/4e2e7b2258dcb671ad7fbafa59128a5d"},"description":"EFSA was asked by the European Commission to assess the scienti\ufb01c quality of newly available human in vitro studies on dermal absorption and, based on the","breadcrumb":{"@id":"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/#primaryimage","url":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/07\/mosquito-bite-2117420_1920.jpg","contentUrl":"https:\/\/lynxee.consulting\/wp-content\/uploads\/2017\/07\/mosquito-bite-2117420_1920.jpg","width":1920,"height":1440},{"@type":"BreadcrumbList","@id":"https:\/\/lynxee.consulting\/en\/europe-new-efsa-gd-on-dermal-absorption\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/lynxee.consulting\/en\/"},{"@type":"ListItem","position":2,"name":"EUROPE: New EFSA GD on Dermal absorption"}]},{"@type":"WebSite","@id":"https:\/\/lynxee.consulting\/#website","url":"https:\/\/lynxee.consulting\/","name":"Lynxee consulting","description":"Innovative support for regulatory issues","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lynxee.consulting\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/lynxee.consulting\/#\/schema\/person\/4e2e7b2258dcb671ad7fbafa59128a5d","name":"\u00c9milie Vianay","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1596a005fffeecedac691970c998238f8639d0641c3e3c40fcc9044ca512b7f3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1596a005fffeecedac691970c998238f8639d0641c3e3c40fcc9044ca512b7f3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1596a005fffeecedac691970c998238f8639d0641c3e3c40fcc9044ca512b7f3?s=96&d=mm&r=g","caption":"\u00c9milie Vianay"},"sameAs":["https:\/\/lynxee.consulting"],"url":"https:\/\/lynxee.consulting\/en\/author\/emilie\/"}]}},"_links":{"self":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/2324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/comments?post=2324"}],"version-history":[{"count":1,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/2324\/revisions"}],"predecessor-version":[{"id":2325,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/posts\/2324\/revisions\/2325"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media\/2321"}],"wp:attachment":[{"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/media?parent=2324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/categories?post=2324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lynxee.consulting\/en\/wp-json\/wp\/v2\/tags?post=2324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}